2026-01-07 - Analysis Report
Okay, here's a comprehensive report on Intuitive Surgical (ISRG), based on the data you provided.

**1) Return Rate Comparison with S&P 500 (VOO)**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets robotic-assisted surgical systems, primarily the da Vinci Surgical System.
*   **ISRG Cumulative Return:** 78.60%
*   **VOO Cumulative Return:** 91.00%
*   **Divergence:**
    *   Current Divergence: -12.4 (VOO outperformed ISRG by 12.4% cumulatively)
    *   Divergence Range: Max: 73.3, Min: -47.8
    *   Relative Divergence: 29.2 (ISRG's performance relative to VOO is near the bottom end of its historical divergence range)

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 49.0% | 29.0% | 45.0% | 1.2 | 60.4 |
| 2017-2019  | 40.0% | 29.0% | 23.0% | 1.4 | 74.5 |
| 2018-2020  | -8.0% | 29.0% | -29.0% | 1.2 | 103.1 |
| 2019-2021  | 26.0% | 21.1% | -17.0% | 1.2 | 135.9 |
| 2020-2022  | -18.0% | 48.9% | -16.0% | 1.2 | 100.3 |
| 2021-2023  | -12.0% | 48.9% | -13.0% | 1.4 | 127.6 |
| 2022-2024  | 35.0% | 38.0% | 16.0% | 1.3 | 197.4 |
| 2023-2025  | 60.0% | 28.0% | -2.0% | 1.2 | 214.2 |

**Analysis:**

*   **Underperformance vs. S&P 500:** ISRG has underperformed the S&P 500 over the period analyzed. The divergence of -12.4% shows the gap in cumulative returns.
*   **Alpha and Beta:**
    *   **Beta consistently around 1.2-1.4:** Suggests ISRG is slightly more volatile than the S&P 500 (Beta of 1).
    *   **Alpha Fluctuations:** The Alpha values vary significantly, showing periods of outperformance and underperformance relative to the S&P 500, especially negative Alphas in more recent periods (2018-2025). This indicates that ISRG's risk-adjusted return has been lower than the S&P 500 in these periods.
*   **CAGR:** The Compounded Annual Growth Rate (CAGR) varies considerably, with some periods showing significant growth (2016-2018, 2023-2025) and others showing negative growth (2018-2020, 2020-2022, 2021-2023).
*   **MDD:** The Maximum Drawdown (MDD) shows the largest peak-to-trough decline during each period. ISRG experienced high MDD in recent years, with the 2020-2022 and 2021-2023 periods experiencing drawdowns nearing 50%. This high MDD may be due to macro issues, competition, or any other causes.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** $561.98
*   **Last Market:** Price: $592.85, Previous Close: $566.38, Change: $4.67 (Indicates a recent positive movement)
*   **5-day SMA:** $570.84
*   **20-day SMA:** $565.42
*   **60-day SMA:** $540.17

**Analysis:**

*   **Recent Uptrend:** The current price of $592.85 and the fact that the 5-day SMA is above the 20-day SMA and both are above the 60-day SMA suggests a recent uptrend in the stock price.

**3) RSI, PPO Index, and Other Indicators**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 60.21 (Neutral - Neither overbought nor oversold)
*   **PPO:** -0.24 (Slightly below zero, indicates a possible downtrend or consolidation)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-23)
*   **Recent Relative Divergence Change (20 days):** -2.3 (Short-term decline)
*   **Expected Return:** 4.3% (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   **MRI:** The MRI suggests a medium investment recommendation, indicating a moderate level of risk.
*   **RSI:** An RSI of 60 is neutral and suggests the stock is not overbought or oversold.
*   **PPO:** The negative PPO suggests a short-term downtrend or consolidation, but the value is not significantly negative.
*   **Hybrid Signal:** The hybrid signal's recommendation to buy suggests a generally positive outlook.
*   **Recent Relative Divergence Change:** The recent decrease in relative divergence suggests a short-term decline in performance compared to the S&P 500.
*   **Expected Return:** The 4.3% expected return suggests moderate long-term outperformance compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Positive Price Target Revisions:** Truist and RBC Capital raised price targets on ISRG.
*   **Long-Term Potential:** Articles from The Motley Fool and The Globe and Mail suggest significant long-term potential (e.g., $1 million for long-term holders, potential for 100% gains by 2030).
*   **Option Activity:** Nasdaq reported notable option activity, indicating investor interest.
*   **Institutional Selling:** Greenleaf Trust sold shares, which could exert downward pressure.
*   **Key Support Level:** Trefis suggests the stock hit a key support level, potentially creating a buying opportunity.

**Analysis:**

*   The news is mixed, with positive price target revisions and bullish articles on long-term potential balanced by institutional selling. The identification of a key support level and option activity suggests potential trading opportunities.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean of 2.06)
*   **Opinions:** 29 analysts
*   **Target Price:** Average: $600.98, High: $700.00, Low: $378.00

**Analysis:**

*   The analyst consensus is "Buy," indicating a positive outlook for the stock. The average target price of $600.98 suggests potential upside from the current price.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-10-22 | 1.98 | 2.51 B$     |
| 2025-07-23 | 1.84 | 2.44 B$     |
| 2025-04-23 | 1.95 | 2.25 B$     |
| 2024-10-18 | 1.59 | 2.04 B$     |
| 2025-10-22 | 1.59 | 2.04 B$     |

**Analysis:**

*   **Revenue Growth:** The revenue generally shows a growth trend, increasing from $2.04B to $2.51B.
*   **EPS Growth:** EPS has also generally increased, although there is some variability. The most recent EPS is $1.98.
* The duplicate of earnings released on 2025-10-22 with a prior date of 2024-10-18 may be an error.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30 | $2.51B  | 66.36%        |
| 2025-06-30 | $2.44B  | 66.31%        |
| 2025-03-31 | $2.25B  | 64.69%        |
| 2024-12-31 | $2.41B  | 68.04%        |
| 2024-09-30 | $2.04B  | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30 | $16.93B | 4.16% |
| 2025-06-30 | $17.85B | 3.69% |
| 2025-03-31 | $17.11B | 4.08% |
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |

**Analysis:**

*   **Consistent Revenue Growth:**  Consistent with the EPS analysis, revenue is growing steadily.
*   **Strong Profit Margins:** Profit margins are consistently high, ranging from 64.69% to 68.04%, indicating strong pricing power and efficient operations.
*   **Equity and ROE:** Equity has generally increased over the period, indicating growth in the company's net worth.  ROE (Return on Equity) fluctuates, but remains in a reasonable range, showing the company's ability to generate profits from shareholder investments.

**7) Comprehensive Analysis (Summary)**

Intuitive Surgical (ISRG) presents a mixed picture:

*   **Recent Stock Performance:** Recent price movement suggests a current uptrend.
*   **Valuation and Risk:** The MRI suggests a medium investment risk, while RSI indicates the stock is neither overbought nor oversold. The PPO suggests caution.
*   **Growth and Profitability:** The company is exhibiting strong revenue and earnings growth with impressive profit margins.
*   **Analyst Sentiment:** Analysts generally have a positive outlook (Buy consensus).
*   **News:** Recent news is a mix of positive price target revisions and institutional selling.
*   **Comparison:**  ISRG has underperformed the S&P 500 in recent periods, but the expected return suggests potential long-term outperformance. Beta shows that the ISRG is more volatile than the S&P 500 (Beta of 1). The Maximum Drawdown (MDD) shows the largest peak-to-trough decline during each period, and the most recent time periods have large MDD values.

**Overall:** ISRG appears to be a company with solid fundamentals and growth prospects, but it has experienced underperformance relative to the S&P 500 in recent times. The positive analyst sentiment and growth in EPS/Revenue is also promising.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.